1. Advocated for increased FY23 funding in the Labor, Health & Human Services, Education, and Related Agencies appropriations bill for HHS/CDC's Infectious Diseases & Opioid Epidemic program to expand access to overdose prevention and other harm reduction services to help prevent skyrocketing overdose deaths nationwide and prevent the transmission of infectious diseases.
Advocated on the effectiveness of overdose prevention centers and the need for the Administration to permit and support this intervention in the U.S. to help save lives by reducing drug overdose deaths.
Advocated for not including or limiting the ban on the use of federal funds to purchase safe supplies for the use of drugs to reduce the transmission of infectious diseases and reduce drug overdoses in H.R. HR 7666, "The Restoring Hope for Mental Health and Well-Being Act of 2022."
Duration: January 1, 2020
to
January 1, 2023
General Issues: Budget/Appropriations , Law Enforcement/Crime/Criminal Justice , Health Issues
Spending: about $350,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2020: House of Representatives, Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), U.S. Senate, Justice - Dept of (DOJ)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2023
Collier Collective, LLC terminated an engagement in which they represented Drug Policy Action on June 8, 2023.
Original Filing: 301472121.xml
1st Quarter, 2023
Collier Collective, LLC terminated an engagement in which they represented Drug Policy Action on June 8, 2023.
Original Filing: 301472122.xml
4th Quarter, 2022
In Q4, Collier Collective, LLC lobbied for Drug Policy Action , earning $40,000. The report was filed on March 12, 2023.
Original Filing: 301447725.xml
Lobbying Issues
1. Advocated for increased FY23 funding in the Labor, Health & Human Services, Education, and Related Agencies appropriations bill for HHS/CDC's Infectious Diseases & Opioid Epidemic program to expand access to overdose prevention and other harm reduction services to help prevent skyrocketing overdose deaths nationwide and prevent the transmission of infectious diseases.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocated on the effectiveness of overdose prevention centers and the need for the Administration to permit and support this intervention in the U.S. to help save lives by reducing drug overdose deaths.
Agencies Lobbied
Justice - Dept of (DOJ)
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Advocated for not including or limiting the ban on the use of federal funds to purchase safe supplies for the use of drugs to reduce the transmission of infectious diseases and reduce drug overdoses in H.R. HR 7666, "The Restoring Hope for Mental Health and Well-Being Act of 2022."
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2022
In Q3, Collier Collective, LLC lobbied for Drug Policy Action , earning $40,000. The report was filed on Dec. 12, 2022.
Original Filing: 301423786.xml
Lobbying Issues
1. Advocated for increased FY23 funding in the Labor, Health & Human Services, Education, and Related Agencies appropriations bill for HHS/CDC's Infectious Diseases & Opioid Epidemic program to expand access to overdose prevention and other harm reduction services to help prevent skyrocketing overdose deaths nationwide and prevent the transmission of infectious diseases.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocated on the effectiveness of overdose prevention centers and the need for the Administration to permit and support this intervention in the U.S. to help save lives by reducing drug overdose deaths.
Agencies Lobbied
Justice - Dept of (DOJ)
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Advocated for not including or limiting the ban on the use of federal funds to purchase safe supplies for the use of drugs to reduce the transmission of infectious diseases and reduce drug overdoses in H.R. HR 7666, "The Restoring Hope for Mental Health and Well-Being Act of 2022."
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2022
In Q2, Collier Collective, LLC lobbied for Drug Policy Action , earning $40,000. The report was filed on Sept. 9, 2022.
Original Filing: 301400056.xml
Lobbying Issues
1. Advocated for increased FY23 funding in the Labor, Health & Human Services, Education, and Related Agencies appropriations bill for HHS/CDC's Infectious Diseases & Opioid Epidemic program to expand access to overdose prevention and other harm reduction services to help prevent skyrocketing overdose deaths nationwide and prevent the transmission of infectious diseases.
2. Advocated on implementation of $30 million in American Rescue Plan Act funding to support overdose prevention, syringe services programs, and harm reduction services authorized and allocated by the American Rescue Plan Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocated on the effectiveness of overdose prevention centers and the need for the Administration to permit and support this intervention in the U.S. to help save lives by reducing drug overdose deaths.
Agencies Lobbied
Justice - Dept of (DOJ)
Type of Issue
Law Enforcement/Crime/Criminal Justice
Lobbying Issues
Advocated for not including or limiting the ban on the use of federal funds to purchase safe supplies for the use of drugs to reduce the transmission of infectious diseases and reduce drug overdoses in H.R. HR 7666, "The Restoring Hope for Mental Health and Well-Being Act of 2022."
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2022
In Q1, Collier Collective, LLC lobbied for Drug Policy Action , earning $30,000. The report was filed on June 2, 2022.
Original Filing: 301376137.xml
Lobbying Issues
1. Advocated for increased FY22 funding in the Labor, Health & Human Services, Education, and Related Agencies appropriations bill for HHS/CDC's Infectious Diseases & Opioid Epidemic program to expand access to overdose prevention and other harm reduction services to help prevent skyrocketing overdose deaths nationwide and prevent the transmission of infectious diseases.
2. Advocated on implementation of $30 million in funding to support overdose prevention, syringe services programs, and harm reduction services authorized and allocated by the American Rescue Plan Act.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocated on the effectiveness of overdose prevention centers and the need for the Administration to permit and support this intervention in the U.S. to help save lives by reducing drug overdose deaths.
Agencies Lobbied
Justice - Dept of (DOJ)
Type of Issue
Law Enforcement/Crime/Criminal Justice
4th Quarter, 2021
In Q4, Collier Collective, LLC lobbied for Drug Policy Action , earning $20,000. The report was filed on Feb. 24, 2022.
Original Filing: 301341924.xml
Lobbying Issues
1. Advocated for increased FY22 funding in the Labor, Health & Human Services, Education, and Related Agencies appropriations bill for HHS/CDC's Infectious Diseases & Opioid Epidemic program to expand access to overdose prevention and other harm reduction services to help prevent skyrocketing overdose deaths nationwide and prevent the transmission of infectious diseases.
2. Advocated for funding to support access to harm reduction programs within the American Rescue Plan Act enacted this Congress. These funds were allocated to HHS/SAMHSA and urged ONDCP & SAMHSA to implement funding expeditiously to support harm reduction programs in need of support as a result of reduced resources during the COVID-19 pandemic.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2021
In Q3, Collier Collective, LLC lobbied for Drug Policy Action , earning $20,000. The report was filed on Nov. 5, 2021.
Original Filing: 301317442.xml
Lobbying Issues
1. Advocated for increased FY22 funding in the Labor, Health & Human Services, Education, and Related Agencies appropriations bill for HHS/CDC's Infectious Diseases & Opioid Epidemic program to expand access to overdose prevention and other harm reduction services to help prevent skyrocketing overdose deaths nationwide and prevent the transmission of infectious diseases.
2. Advocated for funding to support access to harm reduction programs within the American Rescue Act enacted this Congress. These funds were allocated to HHS/SAMHSA and urged ONDCP & SAMHSA to implement funding expeditiously to support harm reduction programs in need of support as a result of reduced resources during the COVID-19 pandemic.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2021
In Q2, Collier Collective, LLC lobbied for Drug Policy Action , earning $20,000. The report was filed on Aug. 7, 2021.
Original Filing: 301293982.xml
Lobbying Issues
1. Advocated for increased FY22 funding in the Labor, Health & Human Services, Education, and Related Agencies appropriations bill for HHS/CDC's Infectious Diseases & Opioid Epidemic program to expand access to overdose prevention and other harm reduction services to help prevent skyrocketing overdose deaths nationwide and prevent the transmission of infectious diseases.
2. Advocated for funding to support access to harm reduction programs within the American Rescue Act enacted this Congress. These funds were allocated to HHS/SAMHSA and urged ONDCP & SAMHSA to implement funding expeditiously to support harm reduction programs in need of support as a result of reduced resources during the COVID-19 pandemic.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2021
In Q1, Collier Collective, LLC lobbied for Drug Policy Action , earning $20,000. The report was filed on May 27, 2021.
Original Filing: 301271824.xml
Lobbying Issues
1. Advocated for increased FY22 funding in the Labor, Health & Human Services, Education, and Related Agencies appropriations bill for HHS/CDC's Infectious Diseases & Opioid Epidemic program to expand access to overdose prevention and other harm reduction services to help prevent skyrocketing overdose deaths nationwide and prevent the transmission of infectious diseases.
2. Advocated for funding to support access to harm reduction programs within the American Rescue Act enacted this Congress. These funds were allocated to HHS/SAMHSA and urged ONDCP & SAMHSA to implement funding expeditiously to support harm reduction programs in need of support as a result of reduced resources during the COVID-19 pandemic.
Agencies Lobbied
U.S. House of Representatives
4th Quarter, 2020
In Q4, Collier Collective, LLC lobbied for Drug Policy Action , earning $20,000. The report was filed on Feb. 17, 2021.
Original Filing: 301248730.xml
Lobbying Issues
1. Create legal protection for overdose prevention centers through the FY21 Commerce, Justice, Science and Related agencies annual appropriations bill.
2. Request $58 million for the CDC Opioid & Infectious Diseases program line in the FY21 Labor, Health and Human Services, Education, and Related Agencies annual appropriations bill.
3. Request a lift of the ban on federal funding for syringe services programs to purchase syringes and other harm reduction equipment.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
1. Advocate for COVID-19 relief for syringe services programs (SSPs) and other harm reduction programs that provide overdose prevention and harm reduction services nationwide, including access to medical and behavioral health care, including treatment for Substance Use Disorder.
2. Lift the ban on federal funding for syringe services programs to purchase syringes and other harm reduction equipment.
Agencies Lobbied
U.S. House of Representatives
3rd Quarter, 2020
In Q3, Collier Collective, LLC lobbied for Drug Policy Action , earning $20,000. The report was filed on Nov. 23, 2020.
Original Filing: 301227306.xml
Lobbying Issues
1. Create legal protection for overdose prevention centers through the FY21 Commerce, Justice, Science and Related agencies annual appropriations bill.
2. Request $58 million for the CDC Opioid & Infectious Diseases program line in the FY21 Labor, Health and Human Services, Education, and Related Agencies annual appropriations bill.
3. Request a lift of the ban on federal funding for syringe services programs to purchase syringes and other harm reduction equipment.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
1. Advocate for COVID-19 relief for syringe services programs (SSPs) and other harm reduction programs that provide overdose prevention and harm reduction services nationwide, including access to medical and behavioral health care, including treatment for Substance Use Disorder.
2. Lift the ban on federal funding for syringe services programs to purchase syringes and other harm reduction equipment.
Agencies Lobbied
U.S. House of Representatives
2nd Quarter, 2020
In Q2, Collier Collective, LLC lobbied for Drug Policy Action , earning $20,000. The report was filed on Aug. 25, 2020.
Original Filing: 301205629.xml
Lobbying Issues
Create legal protection for overdose prevention centers through the FY21 Commerce, Justice, Science and Related agencies annual appropriations bill.
Agencies Lobbied
U.S. House of Representatives
Lobbying Issues
Advocate for COVID-19 relief for syringe services programs (SSPs) that provide overdose prevention and harm reduction services nationwide, including access to medical and behavioral health care, including treatment for Substance Use Disorder.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
In Q1, Collier Collective, LLC lobbied for Drug Policy Action , earning $20,000. The report was filed on May 26, 2020.
Original Filing: 301183617.xml
Lobbying Issues
Create legal protection for overdose prevention centers through the FY21 Commerce, Justice, Science and Related agencies annual appropriations bill.
Agencies Lobbied
U.S. House of Representatives
1st Quarter, 2020
Collier Collective, LLC filed a lobbying registration on May 25, 2020 to represent Drug Policy Action, effective Jan. 1, 2020.
Original Filing: 301183539.xml
Issue(s) they said they’d lobby about: Create legal protection for overdose prevention centers through the FY21 appropriations process. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate
Searching...